1 (Image 01)
Chemical structure of ethynodiol diacetate with molecular weight 384.51, showing its steroid backbone and functional groups.*
Zovia 1/35 Kit
Product Images NDC 51862-894
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Zovia 1/35 (NDC 51862-894). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Mayne Pharma Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
2 (Image 02)
Chemical structure of ethinyl estradiol with molecular weight 296.41, shown as a molecular diagram with related chemical groups and bonds.*
14 (Image 03)
A data table titled 'Percentage of women experiencing an unintended pregnancy during the first year of typical use and the first year of perfect use of contraception and the percentage continuing use at the end of the first year, United States.' It lists contraception methods in the first column, with corresponding percentages for typical use, perfect use, and continuation at one year in separate columns. Methods include spermicide, periodic abstinence, withdrawal, cap, sponge, diaphragm, condom, pill, IUD, injection, implant, and sterilization. Footnotes provide additional context and sources.*
3 (Image 04)
A warning text panel stating that cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use, with the risk notably higher in women over 35 years old and those who smoke heavily (15 or more cigarettes per day). It advises women using oral contraceptives to strongly avoid smoking.*
4 (Image 05)
A bar chart showing mortality rates (number of deaths per 100,000 woman-years) across different age groups (15-24, 25-34, 35-44, and 45+). Data is segmented into four groups: ever-users (non-smokers), controls (non-smokers), ever-users (smokers), and controls (smokers). Mortality rates increase with age, with the highest rates seen in controls who are smokers aged 45 and older.*
5 (Image 06)
A data table showing the annual number of birth-related or method-related deaths associated with fertility control per 100,000 nonsterile women, categorized by fertility control method and age groups from 15 to 44 years. The table compares no fertility control, oral contraceptives for nonsmokers and smokers, IUD, condom, diaphragm/spermicide, and periodic abstinence methods.*
7 (Image 07)
A boxed warning text panel advising that cigarette smoking increases the risk of serious adverse effects on heart and blood vessels for women using oral contraceptives, particularly heavy smokers and women over 35 years old, and strongly advising against smoking while using oral contraceptives.*
15 (Image 08)
A data table showing contraceptive methods, percentages of women experiencing unintended pregnancy during the first year of typical and perfect use, and percentages of women continuing use at one year in the United States. Methods include chance, spermicides, periodic abstinence variants, withdrawal, various barrier methods, pills, IUDs, injections, implants, and sterilization, with associated effectiveness and continuation rates.*
8 (Image 09)
Warning text panel advising that cigarette smoking increases the risk of serious adverse effects on the heart and blood vessels from oral contraceptive use. The risk is higher with age and heavy smoking (15 or more cigarettes per day), especially in women over 35 years of age, with a strong recommendation for women using oral contraceptives not to smoke.*
9 (Image 10)
A data table presenting the annual number of birth-related or method-related deaths per 100,000 nonsterile women by fertility control method and age group. Age groups range from 15-19 to 40-44 years. Methods include no fertility control, oral contraceptives (nonsmoker and smoker), IUD, condom, diaphragm/spermicide, and periodic abstinence. Deaths are differentiated as birth-related or method-related.*
10 (Image 11)
Zovia 1/35 Ethynodiol Diacetate and Ethinyl Estradiol Tablets kit blister card containing 28 tablets. The card is organized by week, with each week showing pale pink active tablets and white inactive tablets, and instructions to take pills from left to right each week. The labeler is Mayne Pharma Inc.*
11 (Image 12)
Instructional diagram showing how to use the Zovia 1/35 oral contraceptive tablet kit by Mayne Pharma Inc. It depicts a hand placing a day label sticker on the blister pack to align with the first day of the user's period. The blister pack contains pale pink active tablets and one white inactive tablet, arranged by day of the week with instructions to take pills from left to right each week.*
12 (Image 13)
13 (Image 14)
Packaging label for Zovia 1/35 kit containing Ethynodiol Diacetate and Ethinyl Estradiol Tablets, USP. The label indicates the product is a prescription medication distributed by Mayne Pharma Inc., Greenville, NC. It includes usage instructions, warnings, and barcodes, with the kit containing 6 blister cards of 28 tablets each.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
